06-08-2024, 10:25 AM
The expansion into china didnt work out as expected. Turns out that it is not like if you are successful in singapore, you can easily replicate the success in china. Tough business environment
06-08-2024, 10:25 AM
The expansion into china didnt work out as expected. Turns out that it is not like if you are successful in singapore, you can easily replicate the success in china. Tough business environment
03-12-2024, 07:13 PM
Sakura Research has published several articles on RMG (2 examples below), including calls for strategic review.
https://sakuraresearch.com/ ----------------------- Raffles Medical Group: Letter to SGX, SIAS, and The Auditor, KPMG LLP (SGX:BSL) https://sakuraresearch.com/?p=312 Raffles Medical Group: Letter to the Board (SGX:BSL) https://sakuraresearch.com/?p=258
07-12-2024, 01:09 PM
(03-12-2024, 07:13 PM)dreamybear Wrote: Sakura Research has published several articles on RMG (2 examples below), including calls for strategic review. Anybody knows the background of Sakura Research? Search the website and find no info about it. Interviewed by Business Times, the "spokesman" prefers to be anonymous. Why so secretive? For the sake of credibility, it's important for small investors to know the background of those who come out with research reports, as well as their agenda.
08-12-2024, 03:43 PM
(07-12-2024, 01:09 PM)Shiyi Wrote: Anybody knows the background of Sakura Research? Search the website and find no info about it. Interviewed by Business Times, the "spokesman" prefers to be anonymous. Why so secretive? hi Shiyi, While it is useful to know the background, but I would also argue that "knowing the background" makes us fall more easily into the halo effect bias. There has been countless posts on VB.com over the years. Of the many that I took counsel of (and then benefitted from), almost all of them were from VBs whom are considered anonymous behind an online persona. End of the day, what really matters is the strength/basis of the analysis, not the reputation of the analyst.
After the temporary boost from operating vaccination centers + pent-up demand upon borders re-opening in April2022, RMG has seen its financials deteriorate in the last 2 years from headwinds like regional competition for medical tourists and rising costs (wage inflation). Its China "luxury" hospitals are probably also taking longer than expected to make a profit (on aggregate) due to the macro situation in China. And that is the "business" part.
Now to the "structure portion" is where it is interesting. It seems like Dr Loo has got bitten by the "value creation and capital efficiency" bug too. ![]() Condensed Financial Statements For the six months and full year ended 31 December 2024 In view of its strong positive operating cash flow, the Group has revised its dividend policy to pay out at least 50% of its sustainable earnings annually. Where the Group has more than sufficient financial capacity to fund operational and capital expenditures as well as investments, the Group shall return excess capital to shareholders through: (a) Special dividends; and/or (b) Share buy-backs. In addition to the above dividend, the Group intends to buy back up to 100 million ordinary shares (approximately 5.3% of total issued ordinary shares) over the next two years. These re-purchased shares will be kept as treasury shares in the first instance adding to the existing 26.4 million shares held. A portion of these Treasury shares will be used to fulfill issuances under the Raffles Medical Group Employee Incentive Schemes. Excess Treasury shares may be cancelled in the future. The intention of these capital management initiatives is to optimise our capital structure, return excess cash, improve return of equity (ROE), and achieve earnings per share accretion. RMG FY24 results: https://links.sgx.com/FileOpen/RafflesMe...eID=833941 |
« Next Oldest | Next Newest »
|